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associated with obesity and atherogenic
dyslipidemia: a cross-sectional study
Alba Guasch1,2, Mònica Bulló1,3*, Antoni Rabassa2, Anna Bonada1,2, Daniel Del Castillo4, Fàtima Sabench4
and Jordi Salas-Salvadó1,2,3,5*Abstract
Background: Low concentrations of plasma vitamin D (25(OH)D) have been associated with the development of
metabolic syndrome (MetS), obesity, diabetes and cardiovascular disease. The objective of this study was to quantify
the associations between 25(OH)D and parathormone (PTH) plasma levels and obesity, the presence of MetS,
diabetes or atherogenic dyslipidemia (AD) in a large sample of individuals with different degrees of adiposity.
Methods: Retrospective study of all patients who had attended the obesity clinics in a Spanish hospital between
2009 and 2011, and whose concentrations of PTH, 25(OH)D, calcium and alkaline phosphatase had been
determined (n=316, 75.9% women). Individuals were categorized by degree of adiposity, presence of MetS, and
other comorbidities.
Results: PTH increased but 25(OH)D and calcium decreased with increasing adiposity. The prevalence of 25(OH)D
deficiency or insufficiency increased with obesity (<10% when BMI<45kg/m2, and 26% when >50). The prevalence
of hyperparathyroidism increased from 12% in non-obese to 47.5% in morbidly obese individuals with BMI>50 kg/m2.
Low plasma 25(OH)D and high PTH concentrations were associated with an increased risk of MetS and AD. These
associations disappeared, except in the case of AD for 25(OH)D when adjusting for BMI. Regression analysis revealed that
BMI and age or seasonality were independent predictors of PTH and 25(OH)D levels, respectively.
Conclusions: BMI was the variable most strongly associated with plasma 25(OH)D and PTH concentrations in our study.
Low 25(OH)D and high PTH concentrations were not independently associated with an increased risk of MetS, or
diabetes. Our data support a possible contribution of plasma 25(OH)D to the pathogenesis of hypertriglyceridemia and
AD through inflammation.
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Obesity has become a serious health problem in most
developed countries. The World Health Organization
estimated that in 2008 the global prevalence of over-
weight and obesity was around 1.5 billion and 500 mil-
lion adults, respectively. Obesity is also well known to be
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and total mortality [1].
Vitamin D deficiency is also an important worldwide
public health problem [2]. Although the most-studied
and best-known function of vitamin D, together with
parathyroid hormone (PTH), is related to bone metabol-
ism [3], many studies show evidence of the relationship
between obesity and low levels of 25(OH)D (the best in-
dicator of clinical levels of vitamin D) [4,5]. Factors
known to influence 25(OH)D concentrations include
race, vitamin D intake, sun exposure, adiposity, age and
physical activity [3]. In obese people, low levels of 25
(OH)D can be attributed mainly to: a) the lowerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adipose tissue [6]; b) the dilution of ingested or cuta-
neously synthesized vitamin D in the enlarged fat mass
[7]; c) low sun exposure, due to mobility limitations or
the low sun exposure of large areas of the body [8]; or d)
a low intake of calcium and vitamin D. The frequently
observed increases in PTH serum concentrations in
obese individuals [9] could be explained by a compensa-
tory mechanism in response to low circulating levels of
25(OH)D.
More recently, vitamin D deficiency has been related
to the pathogenesis of such comorbidities as insulin re-
sistance [10], type 2 diabetes [11], hypertension [12],
dyslipidemia [13], and cardiovascular diseases [14]. A
controversial association has been reported between low
levels of plasma 25(OH)D and/or elevated PTH and the
presence of metabolic syndrome (MetS) and its individ-
ual components,. Some cross-sectional studies note that
decreased levels of 25(OH)D are associated to a higher
risk of MetS after adjusting for various potential con-
founding factors [15,16]. A recent systematic review and
meta-analysis showed that the prevalence of MetS was
reduced by approximately 50% if individuals had high 25
(OH)D concentrations [17]. Other studies showed that
high concentrations of PTH, but not 25(OH)D, were
associated with the presence of the syndrome [18,19].
However, no association has been reported between
PTH or 25(OH)D and MetS in overweight or obese indi-
viduals [20].
In this context, the aim of our study was to evaluate
the associations between 25(OH)D or PTH concentra-
tions and the risk of obesity, and MetS and its individual




The medical records of all patients attending the obesity
outpatient clinics of the Hospital Sant Joan de Reus be-
tween September 2009 and December 2011 were retro-
spectively reviewed. Caucasian individuals who had had
at least one blood test that simultaneously measured
plasma concentrations of PTH, 25(OH)D, calcium, phos-
phate and alkaline phosphatase were included in the
present study.
Exclusion criteria were bariatric surgery before the
blood test, any severe chronic illness, drug or alcohol ad-
diction, endocrine disease (except type 2 diabetes melli-
tus or treated hyperthyroidism), cancer in the previous 5
years, active concomitant inflammatory disease,
advanced liver disease, chronic renal failure and contin-
ued drug treatment with derivatives of vitamin D and
calcium. Subjects were also excluded when primary
hyperparathyroidism was suspected, when plasmaconcentrations of PTH were high (> 6.85 pmol/L) and
hypercalcemia (> 2.5 mmol/L) and/or hypophosphatemia
(<0.8 mmol/L) were present simultaneously. The study
was conducted in agreement with the 1990 Declaration
of Helsinki and subsequent amendments. The Sant Joan
Hospital Ethical Committee from Reus (Spain) approved
the study protocol.
Design
A cross-sectional study was conducted on a population
of individuals with a wide range of adiposity. From the
medical records of the individuals selected we collected
the following data: age, gender, current smoking (absent/
present), presence of comorbidities associated with obes-
ity (type 2 diabetes, hypertension, dyslipidemia), medica-
tion use (fibrates, statins and other lipid lowering agents,
oral antidiabetic agents, insulin and antihypertensive
drugs) and seasonality of blood sampling (winter: De-
cember-February, spring: March-May, summer: June-
August, autumn: September-November). Weight and
height were measured with individuals wearing light
clothing and without shoes using calibrated scales and a
wall-mounted stadiometer (scale capacity of 220 kg
and a precision of 50 g, and a measuring range between
60–200 cm with an accuracy of 1 mm). BMI was calcu-
lated by dividing the weight (in kg) by the square of the
height (in meters). Blood pressure was measured with a
mercury sphygmomanometer adapted to the subject’s
BMI, and after the subject had been seated for at least
five minutes.
Individuals were classified into different categories of
adiposity using the BMI-based index of the Spanish So-
ciety for the Study of Obesity (SEEDO) [21]. The MetS
was defined according to the updated NCEP-ATP III cri-
teria [22], which require three or more of the following
conditions to be met: abdominal obesity (waist circum-
ference >102 cm in men and >88 cm in women), hyper-
triglyceridemia (triglyceride level 150 mg/dL or 1.7
mmol/L or taking triglyceride-lowering medication), low
HDL cholesterol (<40 mg/dL or 1.0 mmol/L in men and
<50 mg/dL or 1.3 mmol/L in women), elevated fasting
blood glucose (100 mg/dL or 5.6 mmol/L or taking anti-
diabetic medication), and elevated blood pressure (sys-
tolic 130 mm Hg, diastolic 85 mm Hg, or taking
antihypertensive medication). Participants who were
being treated with antidiabetic, antihypertensive or
triglyceride-lowering medication were considered to be
diabetic, hypertensive, or hypertriglyceridemic, respect-
ively. Atherogenic dyslipidemia was defined when high
plasma triglycerides and low HDL-concentrations were
concomitantly present. We considered that those
patients for whom we had no waist circumference meas-
urement complied with the criterion of abdominal obes-
ity when their BMI was higher than 35 kg/m2.
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Blood samples were obtained after an overnight fast.
Plasma concentrations of glucose, calcium, phosphate,
alkaline phosphatase, total cholesterol, HDL cholesterol,
LDL cholesterol, triglycerides, creatinine, serum albu-
min, erythrocyte sedimentation rate (ESR) and leukocyte
count were determined following routine biochemical la-
boratory protocols. The corrected calcium level based
on the serum albumin concentrations was calculated as:
Corrected calcium (mmol/L) = measured total Ca
(mmol/L) + 0.02 (40 - serum albumin [g/L]), where 40
represents the average albumin level in g/L. The ultra-
sensitive C Reactive Protein (uCRP) was determined by
immunoturbidimetry. Serum 25(OH)D was determined
by electrochemiluminiscence immunoassay using a
Cobas autoanalyzer (Roche Diagnostics, West Sussex,
UK; intra- and inter-assay CVs <8% and <10%, respect-
ively). Intact PTH were determined by chemilumines-
cent enzyme-labeled immunometric assay using an
IMMULITE 2000 Systems analyzer (Siemens, Gwynedd,
UK; intra- and inter-assay CVs <5% and <8%,
respectively).
The normal, insufficient and deficient vitamin D sta-
tuses were defined as serum concentrations of 25(OH)D
>75.00 nmol/L, between 25.00 and 75.00 nmol/L, and
<25.00 nmol/L, respectively [23]. Secondary hyperpara-
thyroidism was diagnosed in individuals with serum con-
centrations of PTH > 6.85 pmol/L.Statistical analysis
Data are given as means (95% confidence interval, 95%
CI) for continuous variables or percentages for categor-
ical variables, unless otherwise stated. Differences between
groups were tested using one way analysis of variance
(ANOVA) for continuous data and the chi-square test
(χ2) for categorical data. The studied population was
divided into six BMI ranges (<30, 30–35, 35–40, 40–45,
45–50 and >50 Kg/m2). To evaluate predictors of 25(OH)
D and PTH, a regression analysis was performed with
age, gender, BMI, plasma HDL and LDL cholesterol, tri-
glycerides, glucose, the season when the blood sample
was obtained [categorized as summer (March to August)
or winter (September to February)], and presence of
hypertension as covariates (Model 1). In a separate ana-
lysis (Model 2), uCRP and leucocytes were added to
Model 1 as covariates.
Multiple logistic regressions with predefined explana-
tory variables were used to assess odds for MetS, com-
ponents of the MetS and atherogenic dyslipidemia. Four
separate multiple logistic regression models were fitted.
In the first model, serum PTH, 25(OH)D and calcium
were entered into a multiple logistic regression analysis
with MetS (yes/no), presence of MetS components (yes/no) and atherogenic dyslipidemia (yes/no) as dependent
variables. In the second model, age, gender, season of
blood sampling and current smoking were added to
model 1 as confounding variables. In the third model
(model 3), BMI was also included. In the fourth model,
uCRP and leucocytes were included. A statistical signifi-
cance level of 5% was chosen. The analyses were imple-
mented using the SPSS 19.0 statistical package.Results
The general characteristics of the studied population are
shown in Table 1. A total of 316 patients met the inclu-
sion criteria and were included in the analyses. Of these
75.9% (n = 240) were women. The prevalence of MetS
was 62.0%, with no significant differences between the
sexes. High blood pressure was the most common fea-
ture of MetS observed in both sexes. Blood pressure and
plasma concentrations of glucose, triglycerides, albumin
and creatinine were significantly higher, and plasma
HDL and LDL cholesterol, and ESR were lower in men
than in women. Women showed lower plasma concen-
trations of 25(OH)D and calcium than males.
Table 2 describes the characteristics of the patients in
the various BMI ranges. A higher proportion of women
were observed among those with a BMI higher than 35
kg/m2. The prevalence of MetS and its features (abdom-
inal obesity, elevated blood pressure, hyperglycemia, and
low HDL-c) increased when the BMI range was
increased. Although there were no significant differences
in blood pressure, LDL cholesterol and plasma triglycer-
ides across BMI ranges, plasma glucose, ultrasensitive
uCRP, ESR and leukocyte counts increased and HDL
cholesterol and albumin decreased when the BMI range
increased.
Significant mean differences in plasma calcium
(P<0.046), 25(OH)D (P<0.001) and PTH (P<0.001) con-
centrations were observed across the individuals categor-
ized by BMI. Individuals with lower BMI had higher
plasma concentrations of 25(OH)D and calcium than
individuals with higher BMI (Table 2). The concentra-
tions of PTH increased as BMI ranges increased. No
mean differences were found in plasma phosphate and
alkaline phosphatase concentrations between BMI
groups.
Table 3 shows the vitamin D status and the prevalence
of secondary hyperparathyroidism for the BMI categor-
ies. The prevalence of vitamin D deficiency and insuffi-
ciency increased with obesity (by <10% in individuals
with BMI <45 kg/m2, and 26% in those >50 kg/m2).
When vitamin D deficiency and insufficiency were
merged, only 38% of individuals with a BMI lower than
30 kg/m2 had vitamin D insufficiency or deficiency,
compared to 88-95% of those with a BMI higher than 35
Table 1 Characteristics of the study population
Variables Total (n=316) Men (n=76) Women (n=240) P*
Age (years) 46.85 (45.44, 48.26) 49.28 (46.31, 52.24) 46.08 (44.49, 47.68) 0.056
Weight (Kg) 105.29 (102.30, 108.28) 111.06 (103.77, 118.36) 103.46 (100.28, 106.65) 0.032
BMI (Kg/m2) 40.02 (38.94, 41.09) 37.67 (35.29, 40.05) 40.76 (39.56, 41.96) 0.016
Presence of metabolic syndrome 62.0% 61.8% 62.1% 1.000
Abdominal obesity 69.9% 50.0% 75.8% <0.001
Elevated blood pressure 83.4% 91.4% 80.4% 0.039
Elevated fasting glucose 55.6% 61.3% 53.8% 0.287
Reduced HDL cholesterol 61.8% 54.2% 64.1% 0.165
Elevated fasting triglycerides 30.0% 45.1% 25.4% 0.003
Current smoking 20.6% 21.1% 20.4% 0.620
Seasonality (spring-summer) 39.2% 40.8% 38.8% 0.788
Drugs
Fibrates 2.3% 4.3% 1.7% 0.195
Oral antidiabetic 18.0% 27.6% 15.0% 0.016
Insulin 2.8% 5.3% 2.1% 0.226
Antihypertensive 34.2% 48.7% 29.6% 0.003
Systolic blood pressure (mmHg) 139.99 (137.35, 142.63) 146.39 (140.83, 151.95) 137.61 (134.68, 140.54) 0.003
Diastolic blood pressure (mmHg) 84.01 (82.50, 85.52) 87.68 (84.88, 90.47) 82.65 (80.89, 84.41) 0.003
Glucose (mmol/L) 6.05 (5.83, 6.27) 6.57 (5.99, 7.15) 5.88 (5.66, 6.11) 0.009
HDL cholesterol (mmol/L) 1.22 (1.17, 1.26) 1.06 (0.97, 1.15) 1.27 (1.21, 1.32) <0.001
LDL cholesterol (mmol/L) 3.22 (3.11, 3.32) 2.91 (2.68, 3.14) 3.31 (3.19, 3.42) 0.002
Triglycerides (mmol/L) 1.48 (1.37, 1.58) 1.74 (1.45, 2.02) 1.39 (1.29, 1.49) 0.005
ALAT (μKat/L) 0.36 (0.34, 0.38) 0.41 (0.37, 0.45) 0.35 (0.33, 0.37) 0.014
GT (μKat/L) 0.44 (0.40, 0.49) 0.59 (0.45, 0.73) 0.41 (0.36, 0.45) 0.001
Leucocyte count (x10E9/L) 7.69 (7.43, 7.95) 7.43 (6.75, 8.10) 7.76 (7.47, 8.04) 0.324
Albumin (g/L) 40.25 (39.70, 40.81) 42.04 (40.66, 43.41) 39.80 (39.21, 40.39) 0.001
CRP ultrasensitive (mg/dL) 9.41 (8.30, 10.52) 8.53 (5.37, 11.69) 9.62 (8.46, 10.79) 0.444
ESR (mm/h) 22.67 (20.61, 24.74) 13.10 (10.04, 16.17) 25.03 (22.68, 27.38) <0.001
Calcium (mmol/L) 2.34 (2.33, 2.35) 2.36 (2.34, 2.38) 2.33 (2.32, 2.34) 0.020
Phosphate (mmol/L) 1.16 (1.13, 1.18) 1.13 (1.08, 1.18) 1.16 (1.14, 1.19) 0.294
Alkaline phosphatase (uKat/L) 1.23 (1.17, 1.29) 1.21 (1.06, 1.36) 1.24 (1.17, 1.31) 0.656
Creatinine (mol/L) 63.33 (61.55, 65.12) 80.00 (75.81, 84.20) 59.19 (57.63, 60.74) <0.001
eGFR (ml/min/1.73m2) 103.08 (101.16, 105.20) 98.86 (93.89, 103.83) 104.25 (102.06, 106.44) 0.035
PTH (pmol/L) 5.83 (5.53, 6.14) 5.42 (4.84, 5.99) 5.97 (5.61, 6.32) 0.129
25(OH)D (nmol/L) 56.28 (51.58, 60.98) 65.01 (53.18, 76.83) 53.55 (48.60, 58.49) 0.041
Data are means (95% CI) for continuous variables and % for categorical variables.
*P value comparing males and females: One-way analysis of variance (ANOVA) for continuous variables, and chi-square test (χ2) for categorical variables.
Abbreviations: BMI: Body Mass Index; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; ALAT: Alanine transaminase; GT: Glutamyl transaminase; CRP: C
Reactive Protein; ESR: Erythrocyte Sedimentation Rate; eGFR: Estimated Glomerular Filtration Rate; PTH Parathormone; 25(OH)D; 25 Hydroxy-cholecalcipherol.
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from 12% in non-obese subjects to 47.5% in those with a
BMI >50 kg/m2.
In a multivariate analysis (Table 4), BMI, age and
HDL-cholesterol were independent predictors of serum
PTH levels, and together they explain 21% of the vari-
ance in PTH concentrations. For plasma 25(OH)Dconcentrations, BMI and blood sample seasonality were
the independent predictors, explaining 17% of their vari-
ability. When uCRP and leukocyte counts were added to
the model, BMI and uCRP levels explained 12% of the
variability of 25(OH)D concentrations.
In a multiple logistic regression (Table 5), PTH levels
were associated with significantly higher odds of MetS in
Table 2 Characteristics of patients according to body mass index (kg/m2) ranges
BMI (Kg/m2)
<30 (n=50) 30-35 (n=45) 35-40 (n=45) 40-45 (n=81) 45-50 (n=53) >50 (n=42) P*
Age (years) 45.2 (40.2, 50.2) 53.0 (49.3, 56.7) # 44.8 (41.4, 48.3) 45.99 (43.5, 48.5) 46.1 (42.9, 49.2) 47.3 (44.3, 50.4) 0.022
Women 60.8% 60.0% 80.0% 82.7% 84.9% 83.3% 0.002









BMI (Kg/m2) 24.9 (23.9, 26.00) 32.4 (31.9, 32.8) ## 37.3 (36.8, 37.7) ## 42.7 (42.4, 43.0) ## 47.2 (46.8, 47.6) ## 55.2 (53.5, 56.8) ## <0.001
Presence of MetS 19.6% 35.6% 57.8% 79.0% 79.2% 92.9% <0.001
Abdominal
obesity
0.0% 4.4% 100.0% 100.0% 100.0% 100.0% <0.001
Elevated blood
pressure
59.2% 83.3% 78.8% 93.5% 92.7% 93.9% <0.001
Elevated fasting
glucose
31.4% 55.8% 45.5% 60.0% 63.5% 78.6% <0.001
Reduced HDL
cholesterol
14.0% 50.0% 60.5% 76.6% 80.4% 83.3% <0.001
Elevated fasting
triglycerides









142.4 (137.5, 147.4) 141.5 (136.1, 147.0) 144.2 (136.2, 152.2) 0.244
Diastolic blood
pressure (mmHg)
80.1 (76.6, 83.7) 85.6 (81.8, 89.3) 82.4 (77.9, 87.00) 85.3 (82.5, 88.2) 84.4 (80.2, 88.7) 87.0 (82.8, 91.2) 0.087
Glucose (mmol/L) 5.34 (4.88, 5.79) 6.05 (5.59, 6.51) 5.80 (5.35, 6.26) 6.08 (5.63, 6.53) 6.13 (5.59, 6.68) 7.09 (6.21, 7.97) ## 0.002
HDL cholesterol
(mmol/L)
1.60 (1.47, 1.73) 1.21 (1.11, 1.32) ## 1.24 (1.11, 1.36) ## 1.12 (1.05, 1.20) ## 1.07 (0.97, 1.18) ## 1.10 (1.02, 1.17) ## <0.001
LDL cholesterol
(mmol/L)
2.87 (2.58, 3.16) 3.27 (2.95, 3.59) 3.45 (3.18, 3.72) 3.19 (3.01, 3.36) 3.32 (3.05, 3.59) 3.23 (2.93, 3.53) 0.070
Triglycerides
(mmol/L)
1.26 (0.99, 1.54) 1.56 (1.25, 1.87) 1.54 (1.13, 1.95) 1.43 (1.28, 1.58) 1.61 (1.40, 1.82) 1.52 (1.26, 1.77) 0.464
ALAT (μKat/L) 0.35 (0.29, 0.41) 0.32 (0.30, 0.35) 0.35 (0.32, 0.38) 0.36 (0.33, 0.39) 0.38 (0.31, 0.45) 0.40 (0.34, 0.45) 0.430
GT (μKat/L) 0.27 (0.21, 0.32) 0.45 (0.27, 0.63) 0.47 (0.35, 0.59) 0.48 (0.38, 0.59) 0.44 (0.37, 0.50) 0.48 (0.39, 0.57) 0.131
Leucocyte count
(x10E9/L)
6.08 (5.47, 6.70) 6.17 (5.65, 6.70) 7.93 (7.12, 8.74) # 7.99 (7.53, 8.44) ## 8.26 (7.66, 8.86) ## 8.63 (8.01, 9.25) ## <0.001
Albumin (g/L) 47.0 (45.5, 48.5) 41.9 (40.4, 43.3) ## 40.6 (39.4, 41.8) ## 38.8 (38.00, 39.6) ## 38.4 (37.3, 39.5) ## 38.8 (37.5, 40.1) ## <0.001
CRP ultrasensitive
(mg/dL)
2.67 (1.90, 3.45) 4.17 (2.71, 5.63) 7.75 (5.81, 9.68) 9.35 (7.27, 11.44) # 11.16 (8.77, 13.54) # 16.80 (13.07, 20.53) ## <0.001
ESR (mm/h) 14.50 (10.15,
18.85)
18.74 (14.56, 22.92) 18.38 (13.70,
23.05)
21.03 (17.93, 24.12) 26.95 (21.94, 31.96) # 34.84 (27.16, 42.52) ## <0.001
25(OH)D (nmol/L) 95.8 (76.0, 115.5) 59.1 (48.5, 69.7) ## 48.2 (42.3, 54.0) ## 49.8 (42.6, 57.1) ## 46.6 (40.0, 53.2) ## 37.6 (30.3, 44.8) ## <0.001
PTH (pmol/L) 4.27 (3.61, 4.93) 5.11 (4.50, 5.72) 5.84 (5.07, 6.61) 6.05 (5.50, 6.60) # 6.39 (5.68, 7.10) # 7.41 (6.31, 8.52) ## <0.001
Calcium (mmol/L) 2.38 (2.34, 2.41) 2.32 (2.29, 2.35) 2.32 (2.30, 2.35) 2.33 (2.31, 2.35) 2.33 (2.31, 2.36) 2.34 (2.31, 2.36) 0.046
Phosphate
(mmol/L)
1.20 (1.12, 1.27) 1.11 (1.03, 1.19) 1.19 (1.13, 1.26) 1.14 (1.10, 1.18) 1.17 (1.11, 1.22) 1.16 (1.10, 1.21) 0.374
Alkaline phosphatase
(uKat/L)
1.14 (1.04, 1.25) 1.13 (1.02, 1.24) 1.30 (1.15, 1.46) 1.23 (1.10, 1.35) 1.21 (1.03, 1.38) 1.42 (1.19, 1.64) 0.132
eGFR
(ml/min/1.73m2)
105.1 (99.3, 110.8) 99.1 (91.6, 106.6) 101.9 (97.1, 106.6) 105.0 (101.7, 108.4) 103.2 (98.0, 108.5) 102.4 (96.7, 108.1) 0.627
Data are means (CI) for continuous variables and % for categorical variables.
*P value by one-way analysis of variance (ANOVA) for continuous variables, and chi-square test (χ2) for categorical variables.
# Statistical significance compared to the first BMI group (BMI<30 Kg/m2): #P <0.05 and ##P <0.001 by ANOVA, Bonferroni posthoc test.
Abbreviations: BMI: Body Mass Index; MetS: Metabolic Syndrome; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; ALAT: Alanine transaminase;
GT: Glutamyl transaminase; uCRP: ultrasensitive C Reactive Protein; ESR: Erythrocyte Sedimentation Rate; PTH Parathormone; 25(OH)D; 25.Hydroxy-cholecalcipherol;
eGFR: Estimated Glomerular Filtration Rate.
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Table 3 Vitamin D status and presence of hyperparathyroidism according to body mass index (kg/m2) ranges
BMI (kg/m2)
<30 (n=50) 30-35 (n=45) 35-40 (n=45) 40-45 (n=81) 45-50 (n=53) >50 (n=42) P*
Vitamin D status
Deficient 8.0% 9.1% 9.1% 9.1% 12.0% 26.2% <0.001
Insufficient 30.0% 63.6% 81.8% 80.5% 76.0% 69.0%
Optimal 56.0% 27.3% 9.1% 10.4% 12.0% 4.8%
Hyperparathyroidism 12.0% 15.6% 37.5% 29.9% 36.0% 47.5% 0.001
* P value from the Chi-square test (χ2).
Abbreviations: BMI: Body Mass Index.
Vitamin D status by 25(OH)D concentration: deficient (< 25 nmol/L), insufficient (25–75 nmol/L) and optimal (>75 nmol/L).
Hyperparathyroidism: parathyroid hormone concentration > 6.85 pmol/L.
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(models 2, 3 and 4). PTH was also positively associated
with elevated blood pressure and reduced HDL choles-
terol components of the MetS (models 1 and 2). How-
ever, these associations disappeared when adjusted for
BMI. PTH was associated with higher odds of athero-
genic dyslipidemia in both model 1 and model 2, but notTable 4 Predictors of PTH and 25(OH)D by multiple regressio
Model 1 β 95% CI P* R2
PTH (pmol/L) (n=229)
BMI (kg/m2) 0.331 0.045, 0.119 <0.001
Age (years) 0.263 0.025, 0.079 <0.001
Gender 0.050 −0.471, 1.097 0.433
c-HDL (mmol/L) −0.162 −1.959, -0.129 0.026
c-LDL (mmol/L) 0.077 −0.140, 0.584 0.228 0.211
TG (mmol/L) −0.093 −0.851, 0.141 0.159
Glucose (mmol/L) −0.092 −0.301, 0.058 0.183
Seasonality −0.138 −1.415, -0.102 0.024
Hypertension 0.031 −0.735, 1.168 0.654
25(OH)D (nmol/L) (n=234)
BMI (kg/m2) −0.324 −2.103, -0.801 <0.001
Seasonality −0.151 −25.459, -2.834 0.014
Age (years) 0.032 −0.341, 0.560 0.633
Gender −0.112 −25.299, 1.781 0.088
c-HDL (mmol/L) 0.079 −7.362, 25.292 0.280 0.171
c-LDL (mmol/L) −0.007 −6.617, 5.911 0.912
TG (mmol/L) −0.081 −13.394, 3.268 0.232
Glucose (mmol/L) 0.017 −2.624, 3.347 0.812
Hypertension 0.014 −15.052, 18.421 0.843
* P value by multiple regression analysis.
Abbreviations: PTH Parathormone; BMI: Body Mass Index; 25(OH)D: 25.Hydroxy-chole
Model 1. Potential predictors are age, gender, BMI, c-HDL, c-LDL, TG, glucose, seaso
Model 2. Potential predictors are age, gender, BMI, c-HDL, c-LDL, TG, glucose, seasoafter adjustment for BMI (model 3). High 25(OH)D
levels were significantly associated with lower odds of
MetS, and reduced HDL cholesterol and diabetes/hyper-
glycemia components of the MetS in models 1 or 2, but
not after the final adjustment for BMI (models 3 and 4).
High 25(OH)D levels were significantly associated with
lower odds of elevated triglyceride components of then analysis
Model 2 β 95% CI P* R2
PTH (pmol/L) (n=180)
BMI (kg/m2) 0.291 0.032 – 0.129 0.001
Age (years) 0.187 0.007, 0.070 0.018
Gender 0.062 −0.609, 1.438 0.425
c-HDL (mmol/L) −0.171 −2.403, -0.029 0.045
c-LDL (mmol/L) 0.067 −0.235, 0.625 0.373
TG (mmol/L) −0.134 −1.114, 0.103 0.103 0.146
Glucose (mmol/L) −0.077 −0.308, 0.110 0.350
Seasonality −0.101 −1.316, 0.221 0.162
Hypertension 0.044 −0.803, 1.420 0.584
CRP (mg/dL) −0.034 −0.060, 0.039 0.672
Leucocyte count (x10E9/L) 0.027 −0.153, 0.218 0.731
25(OH)D (nmol/L) (n=186)
BMI (kg/m2) −0.238 −1.357, -0.212 0.008
CRP (mg/dL) −0.195 −1.289, -0.133 0.016
Age (years) 0.013 −0.334, 0.395 0.869
Gender −0.039 −15.284, 9.172 0.622
c-HDL (mmol/L) 0.010 −13.590, 15.323 0.906
c-LDL (mmol/L) −0.114 −8.973, 1.195 0.133 0.120
TG (mmol/L) −0.088 −10.637, 3.121 0.282
Glucose (mmol/L) 0.076 −1.251, 3.478 0.354
Seasonality −0.130 −17.153, 0.731 0.072
Hypertension −0.030 −15.748, 10.713 0.708
Leucocyte count (x10E9/L) 0.109 −0.652 – 3.745 0.167
calcipherol CRP: C Reactive Protein.
n and presence of hypertension.
n, presence of hypertension, CRP and leucocyte count.
Table 5 Odds for prevalent metabolic syndrome, metabolic syndrome components and atherogenic dyslipidemia
according to levels of PTH and 25(OH)D
Dependent variable Model I Model 2 Model 3 Model 4
Explanatory variables OR (95% CI) P* OR (95% CI) P* OR (95% CI) P* OR (95% CI) P*
Metabolic syndrome
PTH 1.13 (1.01, 1.26) 0.027 1.10 (0.98, 1.24) 0.090 0.93 (0.81, 1.07) 0.309 0.99 (0.83, 1.17) 0.880
25(OH) 0.99 (0.98, 1.00) 0.004 0.99 (0.98, 1.00) 0.004 1.00 (0.99, 1.01) 0.825 1.00 (0.99, 1.02) 0.690
Age 1.02 (1.00, 1.05) 0.027 1.04 (1.01, 1.07) 0.005 1.04 (1.01, 1.08) 0.011
BMI 1.20 (1.14, 1.26) <0.001 1.21 (1.13, 1.30) <0.001
Elevated blood pressure
PTH 1.40 (1.17, 1.68) <0.001 1.26 (1.03, 1.54) 0.027 1.10 (0.88, 1.39) 0.409 1.15 (0.88, 1.51) 0.297
25(OH)D 1.00 (0.99, 1.00) 0.219 0.99 (0.98, 1.00) 0.141 1.00 (0.99, 1.01) 0.677 1.00 (0.98, 1.01) 0.825
Age 1.07 (1.04, 1.10) <0.001 1.06 (1.03, 1.10) <0.001 1.03 (0.99, 1.07) 0.117
BMI 1.13 (1.06, 1.20) <0.001 1.14 (1.05, 1.23) 0.002
Reduced HDL cholesterol
PTH 1.13 (1.01, 1.27) 0.031 1.16 (1.03, 1.31) 0.015 1.05 (0.92, 1.19) 0.446 1.07 (0.93, 1.24) 0.352
25(OH)D 0.99 (0.98, 0.99) 0.001 0.99 (0.98, 0.99) 0.001 0.99 (0.99, 1.00) 0.180 1.00 (0.98, 1.01) 0.618
BMI 1.11 (1.07, 1.16) <0.001 1.09 (1.04, 1.14) <0.001
Elevated fasting triglycerides
PTH 0.93 (0.84, 1.04) 0.208 0.92 (0.82, 1.03) 0.136 0.90 (0.80, 1.01) 0.080 0.86 (0.74, 1.00) 0.051
25(OH)D 0.99 (0.98, 1.00) 0.037 0.99 (0.98, 1.00) 0.024 0.99 (0.98, 1.00) 0.060 0.98 (0.97, 1.00) 0.026
Calcium Tertile 1 0.50 (0.26, 0.97) 0.045 0.52 (0.26, 1.05) 0.068 0.53 (0.27, 1.08) 0.079 0.71 (0.30, 1.65) 0.423
Tertile 2 0.51 (0.27, 0.97) 0.040 0.51 (0.26, 0.99) 0.047 0.50 (0.25, 0.97) 0.041 1.00 (0.45, 2.22) 0.998
Diabetes
PTH 1.10 (0.99, 1.22) 0.072 1.02 (0.91, 1.15) 0.733 0.93 (0.82, 1.06) 0.270 0.94 (0.82, 1.01) 0.420
25(OH)D 0.99 (0.99, 1.00) 0.078 0.99 (0.99, 1.00) 0.023 1.00 (0.99, 1.00) 0.449 1.00 (0.99, 1.01) 0.787
Calcium Tertile 1 0.35 (0.19, 0.66) 0.001 0.41 (0.20, 0.84) 0.014 0.45 (0.22, 0.93) 0.032 0.46 (0.19, 1.09) 0.079
Tertile 2 0.44 (0.24, 0.80) 0.008 0.48 (0.24, 0.94) 0.034 0.43 (0.21, 0.88) 0.021 0.48 (0.20, 1.12) 0.088
Age 1.07 (1.05, 1.10) <0.001 1.09 (1.06, 1.12) <0.001 1.10 (1.06, 1.14) <0.001
BMI 1.09 (1.05, 1.13) <0.001 1.07 (1.02, 1.12) 0.005
Atherogenic dyslipidemia
PTH 1.22 (1.07, 1.40) 0.004 1.18 (1.02, 1.36) 0.022 1.07 (0.92, 1.25) 0.345 1.02 (0.87, 1.20) 0.798
25(OH)D 0.99 (0.98, 0.99) <0.001 0.99 (0.98, 0.99) <0.001 0.99 (0.98, 1.00) 0.032 0.99 (0.98, 1.01) 0.407
Calcium Tertile 1 0.36 (0.16, 0.80) 0.012 0.41 (0.18, 0.92) 0.032 0.41 (0.17, 0.96) 0.040 0.50 (0.19, 1.29) 0.153
Tertile 2 0.41 (0.19, 0.87) 0.021 0.43 (0.19, 0.93) 0.033 0.34 (0.14, 0.80) 0.014 0.46 (0.18, 1.17) 0.102
BMI 1.09 (1.05, 1.14) <0.001 1.11 (1.05, 1.17) <0.001
*P value by multiple logistic regression analysis.
PTH: Parathormone; 25(OH)D: 25.Hydroxy-cholecalcipherol; BMI: Body mass index.
Model 1. Explanatory variables in the multiple logistic regression model were PTH, 25(OH)D and tertiles of calcium.
Model 2. Explanatory variables as in model 1 plus age, gender, season and current smoking.
Model 3. Explanatory variables as in model 2 plus BMI.
Model 4. Explanatory variables as in model 3 plus uCRP and leukocyte count.
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factors.
Higher 25(OH)D levels were associated with signifi-
cantly lower odds of having atherogenic dyslipidemia
(models 1, 2 and 3). This association also disappeared
when the model was additionally adjusted for uCRP con-
centrations and leukocyte count.Discussion
The most important finding of the present study is that
both 25(OH)D and PTH were strongly associated with
adiposity but not with MetS or most of its components.
Several other studies have suggested that low 25(OH)D
status is associated with the development of the MetS
and its individual components. However, our data do
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PTH to the pathogenesis of the MetS in a population
with a wide range of adiposity. Our data are also consist-
ent with previous reports on the high prevalence of
alterations in calcium metabolism [5,24] in obese
subjects.
Traditionally, vitamin D has been the key regulator of
serum calcium metabolism either directly or indirectly
through PTH. However, vitamin D receptors are found
in a wide variety of tissue, including gut, adipose tissue,
cardiac and skeletal muscles, and β-cells [25]. Therefore,
it is not surprising that numerous studies have investi-
gated the potential key role of vitamin D in the patho-
genesis of MetS and its individual components. As
stated in the introduction section, some but not all epi-
demiologic studies conducted in general populations
have demonstrated a relationship between low plasma
25(OH)D concentrations and the presence of MetS or
its individual components [15-17]. Although these epi-
demiological observations are supported by mechanistic
studies, experimental data are limited, especially in obese
populations.
In this regard, a recent cross-sectional study con-
ducted on 380 individuals, more than 80% of whom
were overweight or obese, showed a strong association
between plasma 25(OH)D concentrations and BMI [26].
Individuals with 25(OH)D deficiency had higher odds of
MetS than those who had normal 25(OH)D status, prob-
ably because the authors failed to account for the con-
founding effect of BMI on the association between MetS
and 25(OH)D. In this study, no associations between
plasma 25(OH)D concentrations and the individual
components of MetS were shown [26].
Similar data were obtained by Botella-Carretero et al.
[27] in a Spanish study conducted in a reduced sample
of severely obese subjects. In this study, 25(OH)D defi-
ciency was more prevalent in patients with the MetS
than in those without. In contrast, Hjelmesaeth et al.
[19], and Roislien et al. 2011 [28], failed to find any asso-
ciation between 25(OH)D and MetS, but reported a
positive relationship between PTH plasma levels and
MetS in individuals with morbid obesity. Neither was an
association found between PTH or 25(OH)D and MetS
in overweight or obese individuals from New Zealand
[20] or Spanish morbidly obese patients [29].
There is also some controversy about the effect of low
25(OH)D status on the pathogenesis of obesity-related
metabolic comorbidities and individual components of
the MetS [30]. As far as glucose metabolism is con-
cerned, Forouhi et al. [31] used data from the Medical
Research Council Ely Prospective Study to show that 25
(OH)D concentrations at baseline were inversely related
with a 10-fold risk of hyperglycemia and insulin resist-
ance. Recent studies also suggest that increased levels ofPTH are independently associated with insulin resistance
in individuals with abdominal obesity suggesting a direct
link between PTH and MetS [32].
Similar results have been found in many observational
studies [33,34]. In contrast, the results of intervention
studies are inconclusive, often because they involve the
joint administration of vitamin D3 (cholecalciferol) and
Ca. This makes it difficult to interpret the results, be-
cause it is not clear whether the response observed is
due to vitamin D and/or Ca. In some randomized clin-
ical trials (RCTs) in which cholecalciferol was used as a
single treatment, insulin response to glucose improved
[35,36], but in others it did not. Similar findings were
observed in relation to blood pressure and hypertension.
Despite strong mechanistic evidence, the results of epi-
demiologic studies evaluating the association between 25
(OH)D status and blood pressure are contradictory and
inconclusive. The odds of having high blood pressure
were lower in Australian individuals with higher 25(OH)
D concentrations than in those with lower concentra-
tions [37]. In contrast, 25(OH)D did not predict future
risk of hypertension or increases in blood pressure in
the Tromso Study [38]. Only one RCT using cholecalci-
ferol has been conducted to determine the relationship
between 25(OH)D and blood pressure. Scragg et al. [39]
randomized 189 elderly subjects who received a single
dose (2.5 mg) of cholecalciferol or placebo during the
winter. There was no effect on blood pressure. Likewise,
our study, conducted in a large sample of individuals
with different degrees of obesity, did not show any inde-
pendent relationship between 25(OH)D concentrations
and the odds of having diabetes and/or hypertension.
Vitamin D status has also been inversely related to
atherogenic dyslipidemia in some studies [13,40] but not
others [31,34,41]. For example, plasma triglyceride con-
centrations were lower in US adult individuals in the top
quartile of 25(OH)D than in those in the reference quar-
tile [40]. A positive association has also been observed
between 25(OH)D and plasma HDL-cholesterol concen-
trations [42]. No RCTs have been conducted to directly
analyze the effect of vitamin D supplementation alone
on lipid profile. However, a significant decrease in LDL-
cholesterol and a non-significant increase in HDL-
cholesterol concentrations have recently been observed
after an 18-month period of oral vitamin D3 supplemen-
tation in Saudi T2DM individuals [43]. Treatment with
cholecalciferol associated with energy restriction resulted
in a more pronounced decrease in plasma triglyceride
concentrations than energy restriction alone [44]. How-
ever, long term supplementation with low doses of cho-
lecalciferol (5 to 20 μg) in healthy individuals had no
effect on lipid profile, probably because the doses admi-
nistered were not sufficient to achieve a clinically mean-
ingful effect on lipids [45]. Other RCTs that administered
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release and blood pressure as the main variables reported
no significant effects on lipids [35,36].
Our study demonstrated that there was an association
between 25(OH) concentrations and the hypertriglyceri-
demia component of the MetS, even after adjusting for
several confounders. It also showed an association be-
tween plasma 25(OH)D concentrations and atherogenic
dyslipidemia after adjusting for such potential confound-
ing variables as BMI, which suggests that 25(OH)D sta-
tus may play a role in lipid profile. This association
could be mediated by inflammation, because it disap-
peared when uCRP was introduced as a covariable in
the analysis.
Our results confirm the results of other studies that
show that obese individuals with higher BMI have a
higher risk of vitamin D deficiency and elevated PTH
serum concentrations. When 25(OH)D deficiency and
insufficiency were merged, only 38% of individuals with
a BMI <30 kg/m2 had 25(OH)D insufficiency or defi-
ciency, compared to 88-95% of those with a BMI>35 kg/
m2. The prevalence of hyperparathyroidism increased
from 12% in non-obese individuals to 47.5% in those
with a BMI>50 kg/m2. Consistent with our results, sev-
eral other studies have demonstrated an inverse relation-
ship between BMI and 25(OH)D deficiency for both
sexes, and for BMIs ranging from normal to severe obes-
ity. In cases of severe obesity, the vitamin D abnormal-
ities were usually more prominent. Prevalence of 25
(OH)D deficiency or hyperparathyroidism has been
observed to be as high as >50% or 40%, respectively, in
individuals with a BMI>50 kg/m2. In overweight or
obese women, an increase of 1 kg/m2 in BMI has been
associated with a decrease of 1.21 nmol/L in 25(OH)D
levels [5]. Weight loss has been associated with an in-
crease in peripheral 25(OH)D concentrations [24,46].
Therefore, our data confirm previous reports, and show
that the presence of obesity is a strong predictor of
hypovitaminosis D and hyperparathyroidism.
One reason for the increase in the prevalence of vita-
min D deficiency with increasing adiposity may be the
higher prevalence of non alcoholic steatohepatitis
(NASH) in obesity and insulin resistance states. Vitamin
D3 is converted into 25-OH-vitamin D in the liver, and
vitamin D deficiency is common in patients with
advanced liver disease. In our study we did not include
those patients with advanced liver disease in order to
discount the effect of this condition on vitamin D con-
centrations. In fact, only 1.6% of our population had
ALAT values that were twice as high as the normal cut-
off values (data not shown).
Some of the strengths of our study are the significant
amount of clinical data that were collected in a large
population of people with different degrees of obesity,and the adjustment for potential confounders such as
age, gender, season of blood sampling, current smoking
and BMI. However, our study also has its limitations.
First, cross-sectional studies are inherently limited in
that they cannot establish cause and effect relationships,
and our results may not necessarily be valid in non-
obese or non-white populations. Second, we acknow-
ledge that major biases with retrospective cohort studies
can impact the recall of former exposure to risk vari-
ables. Among the biases that can negatively impact the
veracity of this type of study are selection bias and mis-
classification or information bias as a result of the retro-
spective aspect. Third, in our study we assumed that all
individuals with a BMI higher than 35 kg/m2 met the
abdominal MetS criterion. This could lead to an over-
estimation of MetS prevalence in individuals between 35
and 40 kg/m2. This overestimation is probably minor, as
only 0.5% of the PREDIMED individuals [47] with a BMI
between 30 and 35 kg/m2 had a waist circumference
lower than the criterion established for abdominal obes-
ity (data not shown). However, abdominal obesity may
have been underestimated specially in individuals be-
tween 25 and 30 kg/m2. Finally, considering the diversity
of results obtained in previous reports on the relation-
ship between 25(OH)D and MetS, and the strong associ-
ation found between obesity and MetS in this study, we
cannot discount that the effect of BMI may have over-
whelmed any marginal effect on MetS that could have
been attributed to 25(OH)D.
In conclusion, in our study BMI was the variable that
was most strongly associated with plasma 25(OH)D and
PTH concentrations. Low plasma 25(OH)D and high
PTH concentrations were also associated with an
increased risk of MetS, but these associations disap-
peared after adjustment for BMI. On the other hand,
our data support a possible contribution of plasma 25
(OH)D to the pathogenesis of hypertriglyceridemia,
and atherogenic dyslipidemia through inflammation.
New prospective studies will be needed to confirm these
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